Pharmacotherapy of chronic pulmonary arterial hypertension: value and limitations. Part I: Primary pulmonary hypertension.
Efforts aimed at assessing pharmacotherapy of pulmonary arterial hypertension (PHT) have largely focused on patients with primary PHT, PHT associated with selected connective tissue diseases, and various forms of hypoxic secondary PHT. Part I of this review discusses the value and limitations of a wide variety of vasodilator drugs, oxygen, and warfarin in the treatment of primary PHT with special reference to their effects on pulmonary and systemic hemodynamics, functional capacity, and survival.
Alpert
M A
MA
Division of Cardiology, University of South Alabama, College of Medicine, Mobile.
Concannon
M D
MD
Mukerji
B
B
Mukerji
V
V
D000109:Acetylcholine / Q000627:therapeutic use; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D011464:Epoprostenol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D010100:Oxygen / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D014859:Warfarin; D011464:Epoprostenol; D000109:Acetylcholine; D010100:Oxygen